Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Construction and Pre-Clinical Evaluation of a New Anti-CD19 Chimeric Antigen Receptor

Anne Marijn Kramer, MD, Sara Ghorashian, MD PhD FRCPath, Gordon Weng-Kit Cheung, MSc, Winston Vetharoy, BVSc, Dale Moulding, PhD, Leila Mekkaoui, MSc, Shimobi Onuoha, PhD, Persis J Amrolia, Professor, Martin A Pule, MD PhD

Blood (2016) 128 (22): 1627.

https://doi.org/10.1182/blood.V128.22.1627.1627

Published: 2016

Journal Articles

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

Sara Ghorashian, MD PhD FRCPath, Anne Marijn Kramer, MD, Sarah Jayne Albon, BSc, MSc, Catherine Irving, BSc, Lucas Chan, PhD, Fernanda Castro, PhD, Bilyana Popova, Kim Champion, PhD, Gary Wright, Hong Zhan, PhD, Waseem Qasim, MBBS PhD, Robert Wynn, Rachael Hough, MD BMBS, FRCP, FRCPath, Farzin Farzaneh, Martin A Pule, MD PhD, Persis J Amrolia, Professor

Blood (2016) 128 (22): 4026.

https://doi.org/10.1182/blood.V128.22.4026.4026

Published: 2016

Journal Articles

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL

Waseem Qasim, MBBS PhD, Persis Jal Amrolia, Sujith Samarasinghe, MD PhD, Sara Ghorashian, MD PhD FRCPath, Hong Zhan, PhD, Sian Stafford, PhD, Katie Butler, PhD, Gul Ahsan, Kimberly Gilmour, Stuart Adams, PhD, Danielle Pinner, Robert Chiesa, Steve Chatters, PhD, Sue Swift, PhD, Nicholas Goulden, MD PhD, Karl Peggs, MBBChir, MRCP, FRCPath, Adrian J Thrasher, MD PhD, Paul Veys, Martin Pule, PhD

Blood (2015) 126 (23): 2046.

https://doi.org/10.1182/blood.V126.23.2046.2046

Published: 2015

Journal Articles

Vaccination - a Novel Strategy to Improve the Persistence of CD19CAR Transduced T-Cells in Relapsed Paediatric ALL: Preliminary Results from the CD19TPALL Study

Martin Pule, Sara Ghorashian, MD PhD FRCPath, Laura Clifton-Hadley, PhDBSc, Paul Smith, Soraya Saiagh, Paul Veys, FRCP,FRCPath, Nicholas Goulden, MD PhD, Gary Wright, Ettore Biagi, MD PhD, Bianca Altvater, PhD, Brigitte Dreno, MD, Kim Champion, PhD, Michelle Cummins, MD, Rachael Hough, MDBMBS,FRCP,FRCPath, Martin G. Sauer, MD, Claudia Rossig, MD, Persis Amrolia

Blood (2014) 124 (21): 383.

https://doi.org/10.1182/blood.V124.21.383.383

Published: 2014

Journal Articles

T Cells Engineered For Resistance To Mycophenolate Mofetil Demonstrate Enhanced Expansion and Improved Tumour Control In Immunosuppressed Hosts

James Edward Griffin, MD, Shoa-An Xue, Benjamin J Carpenter, Pedro Velica, PhD, Angelika Holler, Sara Ghorashian, MD, Emma Nicholson, MD, Martin Pule, MD, Ronjon Chakraverty, MD, PhD

Blood (2013) 122 (21): 4486.

https://doi.org/10.1182/blood.V122.21.4486.4486

Published: 2013

Journal Articles

Endogenous T Cell Receptors Drive Non-Specific Suppression by Foxp3 MHC Class I-Restricted T Cell Receptor-Transduced Polyclonal CD4+ T Cells in Models of Graft-Versus-Host Disease.

Benjamin J Uttenthal, MD, Emma Nicholson, MD, Ben Carpenter, MD, Sara Ghorashian, MD, Graham P Wright, PhD, Barry R Flutter, PhD, Shao-An Xue, PhD, Ronjon Chakraverty, MD, PhD, Emma Morris, MD, PhD

Blood (2012) 120 (21): 3152.

https://doi.org/10.1182/blood.V120.21.3152.3152

Published: 2012

Journal Articles

Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+ T Cells

Emma K Nicholson, MD, Maryam Ahmadi, PhD, Angelika Holler, Rebecca Pike, PhD, Ben Carpenter, MD, Sharyn Thomas, PhD, Sara Ghorashian, MD, Shao-An Xue, PhD, Hans Stauss, MD, PhD, Emma Morris, MD, PhD

Blood (2012) 120 (21): 2044.

https://doi.org/10.1182/blood.V120.21.2044.2044

Published: 2012

Journal Articles

Targeting Therapeutic T Cells to Tumour Niches.

Ben Carpenter, MD, Sara Ghorashian, MD, Emma Nicholson, MD, James Edward Griffin, MD, Maryam Ahmadi, PhD, Angelika Holler, Barry Flutter, PhD, Noha Edwards, Hans Stauss, MD, PhD, Emma Morris, MD, PhD, Ronjon Chakraverty, MD, PhD

Blood (2012) 120 (21): 3009.

https://doi.org/10.1182/blood.V120.21.3009.3009

Published: 2012

Journal Articles

CD4 Cells Engineered to Express an MHC Class I Restricted TCR Can Rescue CD8 Cells Tolerized to Tumour-Associated Antigens

Sara Ghorashian, MD, Ben Carpenter, MD, Angelika Holler, Emma Nicholson, MD, Maryam Ahmadi, PhD, Mathias Zech, MD, Clare Bennett, PhD, Shao-An Xue, PhD, Emma Morris, MD, PhD, Hans Stauss, MD, PhD, Ronjon Chakraverty, MD, PhD

Blood (2012) 120 (21): 952.

https://doi.org/10.1182/blood.V120.21.952.952

Published: 2012

Journal Articles

Varying Response to Imatinib in CML Patients with BCR-ABL M244V Mutation.

Jamshid S. Khorashad, MD, Mona Anand, MD, David Marin, MD, Catharina Andreasson, BSc, Sara Ghorashian, MD, Jane F. Apperley, PhD, John M. Goldman, MD, Jaspal S. Kaeda, PhD

Blood (2005) 106 (11): 1986.

https://doi.org/10.1182/blood.V106.11.1986.1986

Published: 2005

Journal Articles

Use of Direct Sequence PCR for ABl Kinase Mutations in Patients with CML Blast Crisis, Treated Prior to the Availability of Imatinib Therapy.

Sara Ghorashian, MD, Anna Babb, MD, Jamshid Khorasan, MD, Jaspal Kaeda, PhD, David Marin, MD, Jane Apperley, MD, PhD

Blood (2005) 106 (11): 2002.

https://doi.org/10.1182/blood.V106.11.2002.2002

Published: 2005

NARROW

Construction and Pre-Clinical Evaluation of a New Anti-CD19 Chimeric Antigen Receptor

A Novel Second Generation CD19 CAR for Therapy of High Risk/Relapsed Paediatric CD19 + Acute Lymphoblastic Leukaemia and Other Haematological Malignancies: Preliminary Results from the Carpall Study

First Clinical Application of Talen Engineered Universal CAR19 T Cells in B-ALL

Vaccination - a Novel Strategy to Improve the Persistence of CD19CAR Transduced T-Cells in Relapsed Paediatric ALL: Preliminary Results from the CD19TPALL Study

T Cells Engineered For Resistance To Mycophenolate Mofetil Demonstrate Enhanced Expansion and Improved Tumour Control In Immunosuppressed Hosts

Endogenous T Cell Receptors Drive Non-Specific Suppression by Foxp3 MHC Class I-Restricted T Cell Receptor-Transduced Polyclonal CD4+ T Cells in Models of Graft-Versus-Host Disease.

Enhancing the Efficacy of T Cell Receptor (TCR) Gene Therapy by Co-Transfer of TCR and Additional CD3 Molecules Into CD4+ T Cells

Targeting Therapeutic T Cells to Tumour Niches.

CD4 Cells Engineered to Express an MHC Class I Restricted TCR Can Rescue CD8 Cells Tolerized to Tumour-Associated Antigens

Varying Response to Imatinib in CML Patients with BCR-ABL M244V Mutation.

Use of Direct Sequence PCR for ABl Kinase Mutations in Patients with CML Blast Crisis, Treated Prior to the Availability of Imatinib Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only